IFLScience on MSN20h
Revolutionary Nasal Nerve Cell "Bridges" For Treating Spinal Injuries To Begin Clinical Trials
Clinical trials are about to begin for a spinal injury treatment using a "bridge" – made of stem cells from the patients’ own ...
manilatimes18h
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum ...
manilatimes18m
Triple Hair Group Enters Into Licensing Agreement with Akums for Therapy-07 in India
Under the terms of the agreement, Akums will fund regulatory and drug development costs and conduct an ICH GCP Phase III clinical trial involving 380 patients or such number as recommended by CDSCO.
Ipsen (OTCMKTS:IPSEY) Stock Passes Above 200 Day Moving Average – What’s Next?
Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.55 and ...
HUB14h
Two Johns Hopkins faculty members elected to National Academy of Medicine
Christopher G. Chute and Jeffrey D. Rothstein are among 100 new members recognized for outstanding professional achievements ...
WNEM Saginaw on MSN20h
Bad Habits that Raise Your Risk for Dementia
Every three seconds, someone in the world develops dementia. Currently, there are more than 55 million people living with dementia worldwide, and that number is expected to double every 20 years. Now ...